ReviewPharmacogenomics and personalized medicine2015
Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics.
Review in Pharmacogenomics and personalized medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Role of genetic polymorphisms in clopidogrel response variability: a systematic review.Open heart · 2023Pooled it
- Pharmacodynamics, pharmacokinetics, and safety of ticagrelor in Chinese patients with stable coronary artery disease.British journal of clinical pharmacology · 2016Trial
- Review
- Co-Existence ofBalkan journal of medical genetics : BJMG · 2023Article
- Pharmacists' Knowledge, and Insights in Implementing Pharmacogenomics in Saudi Arabia.International journal of environmental research and public health · 2022Article
- The expression profile of platelet-derived miRNA in coronary artery disease patients with clopidogrel resistance.Pharmacology research & perspectives · 2021Observational
- Platelet Endothelial Aggregation Receptor 1 Polymorphism Is Associated With Functional Outcome in Small-Artery Occlusion Stroke Patients Treated With Aspirin.Frontiers in cardiovascular medicine · 2021Article
- Influence ofExperimental and therapeutic medicine · 2020Article
- Why we need safer anticoagulant strategies for patients on short-term percutaneous mechanical circulatory support.Intensive care medicine · 2020Article
- Gut Microbiome and Response to Cardiovascular Drugs.Circulation. Genomic and precision medicine · 2019Review
- Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention.Cardiovascular research · 2019Article
- SUPERNOVA: will its energy trigger the formation of a new therapeutic star?Intensive care medicine · 2019Article
- Plasma miR-142 predicts major adverse cardiovascular events as an intermediate biomarker of dual antiplatelet therapy.Acta pharmacologica Sinica · 2019Article
- The risk of clopidogrel resistance is associated with ABCB1 polymorphisms but not promoter methylation in a Chinese Han population.PloS one · 2017Article
- Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.Frontiers in pharmacology · 2017Article
- Low dose aspirin and pregnancy: how important is aspirin resistance?BJOG : an international journal of obstetrics and gynaecology · 2016Review
- [Current state and trend of precision medicine in thrombosis and hemostasis].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Article
- Constellation: a tool for rapid, automated phenotype assignment of a highly polymorphic pharmacogene,NPJ genomic medicine · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In recent years, substantial effort has been made to better understand the influence of genetic factors on the efficacy and safety of numerous medications. These investigations suggest that the use of pharmacogenetic data to inform physician decision-making has great potential to enhance patient care by reducing on-treatment clinical events, adverse drug reactions, and health care-related costs. In fact, integration of such information into the clinical setting may be particularly applicable for antiplatelet and anticoagulation therapeutics, given the increasing body of evidence implicating genetic variation in variable drug response. In this review, we summarize currently available pharmacogenetic information for the most commonly used antiplatelet (ie, clopidogrel and aspirin) and anticoagulation (ie, warfarin) medications. Furthermore, we highlight the currently known role of genetic variability in response to next-generation antiplatelet (prasugrel and ticagrelor) and anticoagulant (dabigatran) agents. While compelling evidence suggests that genetic variants are important determinants of antiplatelet and anticoagulation therapy response, significant barriers to clinical implementation of pharmacogenetic testing exist and are described herein. In addition, we briefly discuss development of new diagnostic targets and therapeutic strategies as well as implications for enhanced patient care. In conclusion, pharmacogenetic testing can provide important information to assist clinicians with prescribing the most personalized and effective antiplatelet and anticoagulation therapy. However, several factors may limit its usefulness and should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.